Gallery
Picture 1
Gern stock forecast 2025 several biotech hedge funds include
New with box
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Several biotech hedge funds include GERN in 2025 growth portfolios. Forecast aligns with broader sector’s median PE expansion post-approval cycles. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Sarepta Therapeutics (SRPT) is soon expected to post earnings of $0.96 per share for the quarter ended March 2025. This estimate indicates a year-over-year change of +31.5%. This quarter's revenue is expected to be $698.2 million, up 68.9% from the year-ago quarter. Portfolio managers evaluate GERN stock forecast 2025 against peer biotech performance; relative strength metrics position Geron in the top quartile for 2025 growth potential.